Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$11.61 - $15.22 $1.29 Million - $1.69 Million
-110,719 Reduced 76.87%
33,321 $387 Million
Q2 2022

Aug 12, 2022

BUY
$14.32 - $19.88 $184,985 - $256,809
12,918 Added 9.85%
144,040 $2.13 Million
Q1 2022

May 12, 2022

SELL
$15.39 - $20.25 $232,096 - $305,390
-15,081 Reduced 10.32%
131,122 $2.54 Million
Q4 2021

Feb 10, 2022

SELL
$15.91 - $18.72 $731,334 - $860,502
-45,967 Reduced 23.92%
146,203 $2.52 Million
Q3 2021

Nov 12, 2021

BUY
$13.06 - $17.24 $270,133 - $356,592
20,684 Added 12.06%
192,170 $3.21 Million
Q2 2021

Aug 12, 2021

SELL
$11.45 - $13.96 $28,201 - $34,383
-2,463 Reduced 1.42%
171,486 $2.3 Million
Q1 2021

May 14, 2021

SELL
$11.06 - $12.87 $105,390 - $122,638
-9,529 Reduced 5.19%
173,949 $2.08 Million
Q4 2020

Feb 12, 2021

SELL
$9.33 - $12.48 $776,741 - $1.04 Million
-83,252 Reduced 31.21%
183,478 $2.27 Million
Q3 2020

Nov 13, 2020

BUY
$10.33 - $14.49 $550,113 - $771,650
53,254 Added 24.95%
266,730 $2.79 Million
Q2 2020

Aug 13, 2020

SELL
$11.49 - $15.26 $1.18 Million - $1.56 Million
-102,486 Reduced 32.44%
213,476 $2.98 Million
Q1 2020

May 13, 2020

BUY
$8.11 - $15.23 $892,018 - $1.68 Million
109,990 Added 53.4%
315,962 $3.72 Million
Q4 2019

Feb 13, 2020

BUY
$10.28 - $14.38 $1.4 Million - $1.96 Million
136,596 Added 196.89%
205,972 $2.92 Million
Q3 2019

Nov 13, 2019

BUY
$10.05 - $14.55 $697,228 - $1.01 Million
69,376 New
69,376 $731,000
Q2 2019

Aug 12, 2019

SELL
$13.1 - $14.95 $327,500 - $373,750
-25,000 Closed
0 $0
Q1 2019

May 13, 2019

BUY
$13.69 - $20.06 $182,077 - $266,798
13,300 Added 113.68%
25,000 $351,000
Q4 2018

Feb 13, 2019

BUY
$13.96 - $18.26 $163,332 - $213,642
11,700 New
11,700 $204,000

Others Institutions Holding INVA

About Innoviva, Inc.


  • Ticker INVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 69,706,000
  • Market Cap $1.24B
  • Description
  • Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...
More about INVA
Track This Portfolio

Track Capital Fund Management S.A. Portfolio

Follow Capital Fund Management S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Capital Fund Management S.A. with notifications on news.